Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?

Table 2 Digestive symptoms and endoscopy diagnosis of patients, n (%)

Baseline factors	Total (n = 439)	14d-EA group (n = 221)	14d-B-quadruple group (n = 218)	P value1	Total (n = 367)	14d-VA group (n = 183)	14d-VAC group (n = 184)	P value2
Digestive symptoms (no/yes)	102/337 (76.77)	56/165 (74.66)	46/172 (78.90)	0.293	75/292 (79.56)	43/140 (76.50)	32/152 (82.61)	0.147
Epigastric distension (no/yes)	303/136 (30.98)	156/65 (29.41)	147/71 (32.57)	0.474	236/131 (35.69)	122/61 (33.33)	114/70 (38.04)	0.346
Sour regurgitation (no/yes)	344/95 (21.64)	171/50 (22.62)	173/45 (20.64)	0.614	268/99 (26.98)	139/44 (24.04)	129/55 (29.89)	0.207
Belching (no/yes)	357/82 (18.68)	182/39 (17.65)	175/43 (19.72)	0.577	307/60 (16.35)	151/32 (17.49)	156/28 (15.22)	0.557
Hiccup (no/yes)	389/50 (11.39)	202/19 (8.60)	187/31 (14.22)	0.064	331/36 (9.81)	167/16 (8.74)	164/20 (10.87)	0.493
Epigastric pain (no/yes)	290/149 (33.94)	146/75 (33.94)	144/74 (33.94)	0.999	230/137 (37.33)	116/67 (36.61)	114/70 (38.04)	0.777
Nausea (no/yes)	386/53 (12.07)	194/27 (12.22)	192/26 (11.93)	0.926	320/47 (12.81)	163/20 (10.93)	157/27 (14.67)	0.283
Vomiting (no/yes)	417/22 (5.01)	210/11 (4.98)	207/11 (5.05)	0.974	352/15 (4.09)	173/10 (5.46)	179/5 (2.72)	0.184
Hematemesis (no/yes)	438/1 (0.23)	221/0 (0.00)	217/1 (0.46)	0.497	367/0 (0.00)	183/0 (0.00)	184/0 (0.00)
Tarry stool (no/yes)	432/7 (1.59)	217/4 (1.81)	215/3 (1.38)	1.000	358/9 (2.45)	178/5 (2.73)	180/4 (2.17)	0.993
Emaciation (no/yes)	427/12 (2.73)	218/3 (1.36)	209/9 (4.13)	0.075	359/8 (2.18)	178/5 (2.73)	181/3 (1.63)	0.715
Halitosis (no/yes)	290/149 (33.94)	153/68 (30.77)	137/81 (37.16)	0.158	249/118 (32.15)	126/57 (31.15)	123/61 (33.15)	0.681
Others (no/yes)	419/20 (4.56)	208/13 (5.88)	211/7 (3.21)	0.180	321/46 (12.53)	158/25 (13.66)	163/21 (11.41)	0.515
Endoscopy diagnosis (no/yes)	140/299 (68.11)	68/153 (69.23)	72/146 (66.97)	0.612	122/245 (66.76)	64/119 (65.03)	58/126 (68.48)	0.483
Atrophic gastritis (no/yes)	358/81 (18.45)	178/43 (19.46)	180/38 (17.43)	0.584	300/67 (18.26)	152/31 (16.94)	148/36 (19.57)	0.515
Non-atrophic gastritis (no/yes)	257/182 (41.46)	126/95 (42.99)	131/87 (39.91)	0.513	222/145 (39.51)	113/70 (38.25)	109/75 (40.76)	0.623
Gastric ulcer (no/yes)	378/61 (13.90)	185/36 (16.29)	193/25 (11.47)	0.144	322/45 (12.26)	159/24 (13.11)	163/21 (11.41)	0.619
Duodenobulbar ulcer (no/yes)	389/50 (11.39)	195/26 (11.76)	194/24 (11.01)	0.803	324/43 (11.72)	159/24 (13.11)	165/19 (10.33)	0.406
Gastritis verrucosa (no/yes)	430/9 (2.05)	216/5 (2.26)	214/4 (1.83)	1.000	361/6 (1.63)	180/3 (1.64)	181/3 (1.63)	1.000
Erosive gastritis (no/yes)	373/66 (15.03)	194/27 (12.22)	179/39 (17.89)	0.096	306/61 (16.62)	149/34 (18.58)	157/27 (14.67)	0.315
Bile reflux gastritis (no/yes)	410/29 (6.61)	205/16 (7.24)	205/13 (5.96)	0.590	341/26 (7.08)	167/16 (8.74)	174/10 (5.43)	0.217
Others (no/yes)	422/17 (3.87)	212/9 (4.07)	210/8 (3.67)	0.827	348/19 (5.18)	170/13 (7.10)	178/6 (3.26)	0.097
History of antibiotics use in 2 years (no/yes)	213/226 (51.48)	114/107 (48.42)	99/119 (54.59)	0.196	175/192 (52.32)	96/87 (47.54)	79/105 (57.07)	0.068

¹P values were obtained from two-sided comparisons of difference between the 14d-EA group and the 14d-B-quadruple group.

²P values were obtained from two-sided comparisons of difference between the 14d-VA group and the 14d-VAC group.

EA: Esomeprazole-amoxicillin; B-quadruple: Esomeprazole-amoxicillin-clarithromycin-bismuth; VA: Vonoprazan-amoxicillin; VAC: Vonoprazan-amoxicillin-clarithromycin.